PFE
Pfizer
Health Care · Pharmaceuticals · US
$25.68
Close 2026-05-10
✓ ETHICAL PASS

NARROW MOAT
HIGH
Data Confidence: 100%
Full financial profile available
Market Cap
$144.3B
Trailing P/E
19.33
Forward P/E
8.91
Rev Growth
+5.4%
Profit Margin
11.8%
ROE
8.3%
Analyst Target
$29.15
Recommendation
BUY
About Pfizer

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Opportunity Summary
Trading at $25 against a fair value of $34, a 26% discount. Passes all ethical screens. Ranks better than 95% of screened stocks.
Ethical Screen
Business ActivityPASS
Debt Ratio (0.31%)PASS
Cash Ratio (0.01%)PASS
Receivables Ratio (0.06%)PASS
Revenue Ratio (0.01%)PASS
OverallPASS
Score Ethical: 84.1
Score Valuation: 90.5
Score Quality: 52.2
Score Combined: 63.0
Fair Value Est: $34.12 · Margin of Safety: +25.8% · Tier: OPPORTUNITY

Full Analysis

Opportunity scores, earnings history, insider transactions, institutional holders, analyst consensus, and more.

Unlock with Membership
Opportunity Scores
Valuation100.0
Quality46.1
Cash Flow100.0
Moat70.0
Balance Sheet77.6
Debt Purity6.9
Liquid Purity98.0
Rev Purity80.7
Compliance55.4
Tier: GOLD · Score: 75.3 · Rank: #157
Earnings History (Last 8 Quarters)
DateEPS Est.Reported EPSSurprise %
2026-07-290.68Pending--
2026-05-050.520.47-9.5%
2026-02-030.570.66+16.2%
2025-11-040.630.87+37.4%
2025-08-050.360.51+41.6%
2025-04-290.670.92+36.5%
2025-02-040.460.63+37.2%
2024-10-290.611.06+73.3%
Quarterly Financials
PeriodRevenueNet IncomeEBITDAGross ProfitOp. IncomeEPS
2026-03-31$14.4B$2.7B$5.5B$10.9B$4.1B0.47
2025-12-31$17.6B-$1.6B$756.0M$12.3B$3.5B-0.29
2025-09-30$16.7B$3.5B$5.6B$12.5B$4.1B0.62
2025-06-30$14.7B$2.9B$5.3B$10.9B$3.8B0.51
2025-03-31$13.7B$3.0B$5.1B$10.9B$4.4B0.52
2024-12-31
Insider Transactions
DateNameRoleSharesValue
2026-03-03DAMICO JENNIFER B.Officer21,719--
2026-02-25SAHNI PAYALOfficer56,888$1.9M
2026-02-25MCDERMOTT MICHAELOfficer37,925$1.3M
2026-02-25DAMICO JENNIFER B.Officer17,558$593.8K
2026-02-25BOURLA ALBERTChief Executive Officer491,626$16.6M
2026-02-25FONSECA LIDIA PH.D.Officer56,888$1.9M
2026-02-25LANKLER DOUGLAS MOfficer122,907$4.2M
2026-02-25BOSHOFF CHRISTOFFELOfficer13,383--
2025-03-04DAMICO JENNIFER B.Officer2,500$64.8K
2025-03-04DAMICO JENNIFER B.Officer5,583--
Top Institutional Holders
HolderSharesValue% Held
Blackrock Inc.498.3M$12.9B0.1%
Vanguard Capital Management LLC369.4M$9.6B0.1%
State Street Corporation301.6M$7.8B0.1%
Geode Capital Management, LLC133.6M$3.5B0.0%
Vanguard Portfolio Management LLC116.7M$3.0B0.0%
Fisher Asset Management, LLC105.0M$2.7B0.0%
Morgan Stanley92.7M$2.4B0.0%
Northern Trust Corporation62.0M$1.6B0.0%
Massachusetts Financial Services Co.56.9M$1.5B0.0%
State Farm Mutual Automobile Insurance Co54.5M$1.4B0.0%
Analyst Recommendations
3 Months Ago
2
9
15
2
29 analysts
2 Months Ago
2
8
15
2
28 analysts
Last Month
2
7
16
2
28 analysts
Current
2
9
15
2
29 analysts
Strong Buy Buy Hold Sell Strong Sell
Recent Price History
2026-05-10
$25.68
2026-05-09
$25.68
2026-05-08
$26.53
2026-05-08
$26.53
5D Range
May 8
May 8
May 9
May 10
Additional Fundamentals
Enterprise Value
$199.6B
Price/Book
1.70
Beta
0.305
Analysts
27
Total Revenue (TTM)
$63.3B
Total Debt
$64.7B
Earnings Growth
-10.1%
Dividend Yield
6.7%
Rec. Mean
2.45
Short Ratio
3.98
Short % Float
0.0%
Employees
75,000

Elite Intelligence

Trade Consideration with position sizing, convergence signals, and risk analysis. Available to Elite members.

Upgrade to Elite
Trade Consideration
The Opportunity
Score 63.0 (P98 — top 2.0% of scored tickers). Narrow Moat. Ethical PASS. 27 analysts at Buy.
Price: $25.68 | Target: $29.19 (+14%) | Fair Value: $34.12 (+33%)
Score
63
Moat
NARROW
Conviction
Standard
Upside
+14%
The Fundamentals
Revenue Growth+5.4%
Profit Margin11.8%
ROE8.3%
Forward P/E8.9
Market Cap$144.3B
Earnings Track Record
DateEstimateReportedSurprise
2026-07-29$0.68Pending
2026-05-05$0.52$0.47-9.5%
2026-02-03$0.57$0.66+16.2%
2025-11-04$0.63$0.87+37.4%
2025-08-05$0.36$0.51+41.6%
2025-04-29$0.67$0.92+36.5%
Position Sizing Scenarios
Stop: $21.83 (-15%) | Entry: $25.68
SharesCostProfit to TargetR:R
To Consensus ($29.19, 27 analysts)
10$256.80+$35.10 (14%)0.9R
50$1,284.00+$175.50 (14%)0.9R
100$2,568.00+$351.00 (14%)0.9R
To Fair Value ($34.12)
10$256.80+$84.40 (33%)2.2R
50$1,284.00+$422.00 (33%)2.2R
100$2,568.00+$844.00 (33%)2.2R
Risk Factors
  • Elevated short interest (3.98 days to cover)
The Verdict
Pfizer passes all ethical screens and holds a narrow competitive moat.
Quantitative Grade

A single score combining all analytical layers below. A is strongest, D is weakest.

C
Quant Score
48.1
Risk Grade
LOW_RISK
Layers
8
Quality: CONSISTENT_BEATER
Risk Profile

How much could this ticker lose on a bad day? These metrics measure worst-case scenarios from historical data.

VaR 95%
-2.4%
worst expected daily loss, 19 in 20 days
CVaR 95%
-3.3%
avg loss on the worst 5% of days
Annual Volatility
Sortino Ratio
0.14
above 1.0 is good
Max Drawdown
-29.0%
Worst Day
Forward Outlook

Based on 10,000 simulated price paths, here is the probability of where this ticker could be in 30, 60, and 90 days.

30d Prob Up
90d Prob Up
Median Return 30d
Liquidity Score
95
Liquidity Grade
HIGHLY LIQUID
Trend & Momentum

What direction is this ticker actually moving, filtered through noise? Is it speeding up or slowing down?

Kalman Trend
Trend Strength
Momentum Signal
HMM Regime
RSI Signal
Technical Signals

Classic chart signals that institutional traders monitor. Golden Cross is bullish, Death Cross is bearish.

MA Crossover
ABOVE_200
Bollinger Position
UPPER_HALF
Beta
Relative Volume
1.8x
Short Interest
Financial Health

Is this company financially sound? The Z-Score measures bankruptcy risk. The F-Score measures fundamental strength.

Altman Z-Score
below 1.81 = distress zone
Piotroski F-Score
Earnings Beat Rate
87.5%
Earnings Consistency
Correlations

These tickers tend to move together (positive) or in opposite directions (negative). Useful for portfolio diversification.

Most Correlated
TickerCorrelation
XLV0.619
AMGN0.564
BMY0.540
DHR0.534
NVS0.533
Inverse Correlated
TickerCorrelation
ANTA-0.121
JPSWY-0.111
VRAYQ-0.109
FLY-0.109
6146.T-0.108
Seasonality

Does this ticker have consistent patterns on certain days or months? Historical tendencies, not guarantees.

Best Day
Friday
Worst Day
Thursday
Best Month
Jan
Worst Month
Apr
Fri-Mon Effect
0.06878779173409022
Earnings Drift

After this company beats earnings, does the price keep going up? Drift tracks post-earnings momentum.

Avg Drift After Beat
-0.9%
Beat Drift Positive %
57.1%
Consistency
Momentum Rankings

How does this ticker's recent performance compare to the entire universe? Ranked across 1, 3, 6, and 12-month returns.

1M Return
-2.7%
3M Return
-3.2%
6M Return
+9.5%
12M Return
+20.0%
Momentum Rank
#2456
Momentum Signal
FLAT

Get our daily market read free. Join thousands of traders.

Free Explorer Access